Hanns Lochmüller is awarded prestigious Tier 1 Canada Research Chair in neuromuscular genomics and health

We are thrilled to announce that Hanns has been awarded a Canada Research Chair (CRC) in Neuromuscular Genomics and Health. The announcement was made at a ceremony at the University of Victoria at noon today. The prestigious Tier 1 CRC awards are for outstanding researchers acknowledged by their peers as world leaders in their fields. The program aims to help chairholders achieve research excellence, improve Canada’s depth of knowledge and quality of life, strengthen the country’s international competitiveness, and train the next generation of highly skilled researchers through student supervision, teaching, and research coordination. In the same announcement CHEO Professor Kym Boycott was awarded a Tier 1 CRC in Rare Disease Precision Health.

Hanns said: “This CRC award is part of what enabled my move from Europe to Canada, and together with our recently awarded CIHR Project grant allows us to establish a really exciting research program in neuromuscular genomics and health here at the CHEO Research Institute in close partnership with the Department of Medicine of The Ottawa Hospital and the Brain and Mind Research Institute of Ottawa University. I’m delighted that Kym Boycott, a long-term friend and collaborator, has also received a Tier 1 chair at the same time: this is a clear demonstration of the strategic importance of rare disease research here in Ottawa and our leadership role will benefit not only Canadian patients but also many others around the world.”

Hanns with research associate and lab manager Sally Spendiff

Find out more

CHEO Research Institute press release

Government of Canada press release

Canada Research Chair program details

Hanns-crc

Read next...

The new clinical trials list provides searchable and filterable information on the current trials the research team are conducting.

Lochmuller Lab clinical research webpage update

It’s now easier than ever to stay up-to-date on the clinical research trials that our team is involved in We are excited to share an...
Periostin paper image

New publication: Periostin as a blood biomarker of muscle cell fibrosis, cardiomyopathy and disease severity in myotonic dystrophy type 1

Lochmüller Lab members published as authors in Journal of Neurology study Myotonic dystrophy is the most common adult-onset muscular dystrophy and affects cardiac and endocrine...
Neuromuscular junction and animal models

New publication: TEFM variants impair mitochondrial transcription causing childhood-onset neurological disease

Lochmüller Lab Members Published as Authors in Nature Communications Study We are excited to share that the study "TEFM variants impair mitochondrial transcription causing childhood-onset...
Sally describes lab research to FSHD visitors

Lochmüller Lab hosts information session on clinical research for FSHD

On Saturday June 11th we were delighted to welcome individuals and families living with facioscapulohumeral muscular dystrophy (FSHD) and members of the FSHD Society to...
JND-cover

May 2022 Issue of the Journal of Neuromuscular Diseases Available Online

The Lochmüller Lab is pleased to share that the the Journal of Neuromuscular Diseases has published its third issue of 2022! In Volume 9, Issue...
CHEO

CHEO Registers Tenth Patient in AMO Reach CDM Clinical Trial

The Lochmüller Lab is excited to share that as of March 14, 2022 our site at the Children’s Hospital of Eastern Ontario (CHEO) has registered...